<DOC>
	<DOCNO>NCT01001923</DOCNO>
	<brief_summary>Primary objective demonstrate activity REGN475/SAR164877 reduce pain associate chronic pancreatitis . Secondary objective : - ass safety tolerability REGN475/SAR164877 patient chronic pancreatitis pain ; - characterize pharmacokinetic , pharmacodynamic , immunogenicity profile REGN475/SAR164877 population ; - measure change total daily dose rescue medication require .</brief_summary>
	<brief_title>Single Injection REGN475/SAR164877 Treatment Chronic Pancreatitis Pain</brief_title>
	<detailed_description>The duration study period participant 14 week , include screen period 2 week , 12-week follow-up injection .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<criteria>Inclusion criterion : Moderate severe abdominal pain due chronic pancreatitis least 6 month duration . Exclusion criterion : Mild pain Pain IntensityNumeric Rating Scale [ PINRS ] screen randomization visit ; Narcotic addiction ; Recent pancreatic surgical endoscopic intervention chronic pancreatitis pain ; Unwillingness use studydefined rescue analgesia exclusively . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>